Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Dec 8;16(1):438.
doi: 10.1186/s12888-016-1158-1.

Probable clozapine-induced parenchymal lung disease and perimyocarditis: a case report

Erlend Bugge  1   2 , Trygve Nissen  1   2 , Rolf Wynn  3   4
Affiliations
Case Reports

Probable clozapine-induced parenchymal lung disease and perimyocarditis: a case report

Erlend Bugge et al. BMC Psychiatry. .

Abstract

Background: Clozapine is the archetypical atypical antipsychotic, its primary indication being treatment resistant schizophrenia. Severe side effects caused by clozapine, including leukopenia, agranulocytosis, and myocarditis, are well known. A rarely described side effect is concurrent perimyocarditis and parenchymal lung disease.

Case presentation: A previously physically healthy 23-year-old male Caucasian that suffered from schizophrenia presented with flu-like symptoms 1 week after starting clozapine treatment. Treatment with clozapine was discontinued. He developed respiratory distress. Investigations showed significant parenchymal infiltration in both of the lungs, pericardial fluid, and heart failure. He initially received treatment for suspected malignant neuroleptic syndrome and later for suspected infection, but these tentative diagnoses were not confirmed. The patient's condition gradually improved. In retrospect, clozapine-induced parenchymal lung disease and perimyocarditis were deemed the most probable causes.

Conclusions: Concurrent perimyocarditis and parenchymal lung disease are rare side effects of clozapine. Clozapine-induced disease in general is considered an exclusion diagnosis. Lacking a verifiable diagnosis when suspecting a side effect of clozapine, clinicians might treat the most likely and serious condition presenting and consider discontinuing clozapine until the diagnostic uncertainty is reasonably resolved.

Keywords: Case report; Clozapine; Diffuse parenchymal lung disease; Pericarditis; Perimyocarditis; Schizophrenia; Side effects.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chest x-ray. Chest x-ray showing massive diffuse parenchymal infiltration, predominantly of the left lung
See this image and copyright information in PMC

References

    1. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O’Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996;169(4):483–8. doi: 10.1192/bjp.169.4.483. - DOI - PubMed
    1. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. New Engl J Med. 1993;329(3):162–7. doi: 10.1056/NEJM199307153290303. - DOI - PubMed
    1. Kilian JG, Kerr K, Lawrence C, Celemajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354(9193):1841–5. doi: 10.1016/S0140-6736(99)10385-4. - DOI - PubMed
    1. Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand. 2015;132(4):231–40. doi: 10.1111/acps.12416. - DOI - PubMed
    1. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust. 2009;190(4):190–2. - PubMed

Publication types